


**Clinical evidence (level I):
Orthopedic surgery, TKA & THA**

Patient and procedure risk stratification backed by clinical evidence

While surgical patients may benefit from Prevena Therapy, patients at high risk for complications such as surgical site infection may see added benefit. The following uses select study data¹⁻⁴ to provide an illustrative guide to aid in risk stratification. This is not an all-inclusive list of risk factors. Clinicians are advised to use their clinical judgment to identify at-risk patients and procedures.

► **Start here**



References

1. Higuera-Rueda C, et al. The Effectiveness of Closed Incision Negative Pressure Therapy versus Silver-Impregnated Dressings in Mitigating Surgical Site Complications in High-Risk Patients after Revision Knee Arthroplasty: The PROMISES Randomized Controlled Trial. J Arthroplasty. 2021 Jul;36(7S):S295-S302.e14. 2. Willy C, et al. Closed incision negative pressure therapy: international multidisciplinary consensus recommendations. Int Wound J. 2017 Apr;14(2):385-398. 3. Newman JM, Siqueira MBP, Klika A, et al. Use of closed incisional negative pressure wound therapy after revision total hip and knee arthroplasty in patients at high risk for infection: A prospective, randomized clinical trial. Journal of Arthroplasty 2019; 34(3):554-559. 4. Singh D, Alton T, Alvand A, et al. Linear and Area Coverage with Closed Incision Negative Pressure Therapy Management: International Multidisciplinary Consensus Recommendations. International Wound Journal, 2025; 22:e7067. <https://doi.org/10.1111/iwj.70677>. [OPEN ACCESS](#)

Advancing the standard of care

Solventum Advanced Wound Care
12930 IH10 W
San Antonio, TX 78249
USA

Phone 800-275-4524
Web Solventum.com

Solventum™ Prevena™ 125 Therapy Unit and Solventum™ Prevena Plus™ 125 Therapy Unit manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, Prevena 125 and Prevena Plus 125 Therapy Units are intended to aid in reducing the incidence of seroma; and, in patients at high risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and Class II wounds.

The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at eifu.solventum.com.

The indication statement does not apply to the Prevena Plus 125 Therapy Unit (14-Day) that comes with the Solventum™ Prevena Restor™ System Kits (see Prevena Restor System Instructions for Use).

Note: Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.

© Solventum 2025. Solventum, the S logo, Prevena and other trademarks are trademarks of Solventum or its affiliates. Other trademarks are the property of their respective owners. US_70-2013-1459-1